10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

AstraZeneca1 个研究点分布在 1 个国家目标入组 1,114 人开始时间: 2009年5月最近更新: 2010年6月29日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 1,114
试验地点: 1
主要终点: The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Cross Sectional

入排标准

年龄范围: 50 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Early Breast Cancer patients
•Postmenopausal Status
•patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

排除标准

•Advanced Breast Cancer patients(stage iii, iv)
•Patients who are hard to be analysed by limitation of chart record according to investigators discretion
•patients who already have been registered in this study

结局指标

主要结局

The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.

时间窗: 1 visit

次要结局

To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer(1 Visit)
To analyse CHD management patterns according to defined 10-year CHD risk categories(1 Visit)
To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk(1 Visit)

研究者

发起方

AstraZeneca

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

尚未招募

3 期

Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerBreast Cancer

NCT06223698Region Örebro County3,832

已完成

不适用

Recurrence Risk Evaluation by 21-gene DetectionRelationship and Consistency Analysis

NCT03841266Xijing Hospital220

招募中

不适用

Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.Chemotherapy EffectTriple Negative Breast CancerRecurrence, Local NeoplasmRisk FactorsBreast Cancer

NCT06441240Fondazione Policlinico Universitario Agostino Gemelli IRCCS933

尚未招募

不适用

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudyHormone-receptor-positive Breast CancerPremenopausal Breast CancerBreast Cancer Patients at Intermediate to High RiskOvarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen

NCT05801705Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University700

尚未招募

不适用

Assessment of Breast cancer risk factors and developing risk prediction model.

CTRI/2022/09/045295Indian Council of Medical Research ICMR